Introduction:
The Almac Group has introduced two state-of-the-art facilities at its Craigavon headquarters in Northern Ireland, pushing its global expansion investment to over £400 million ($500 million).
Features:
These facilities aim to meet the rising demand for commercial manufacturing, packaging, and peptide production, significantly enhancing the capabilities of Almac Pharma Services and Almac Sciences.
The first facility, a 32,000-square-foot space for Almac Pharma Services, greatly increases its capacity for the commercial manufacturing and packaging of sachet drug products.
It features large-scale manufacturing suites, advanced automated packaging technologies, and expanded Quality Control (QC) Laboratory Testing capabilities.
The second facility is a 28,000-square-foot Good Manufacturing Practice (GMP) site for Almac Sciences, more than doubling its peptide Active Pharmaceutical Ingredient (API) manufacturing capacity.
This site enhances synthesis, purification, and isolation processes to better meet the growing demand for clinical and commercial products.
In addition to these new facilities, Almac has established a technology development center, added small molecule API GMP reactors, and set up a dedicated chemical warehouse.
These expansions are part of Almac’s global investment program initiated in June 2022. Other projects include a Centre of Excellence for Commercial Drug Product Partnership.
A CDx Development, Manufacturing, and Commercial center, a GMP facility for drug substance manufacturing, expanded clinical production and distribution capabilities in Souderton, Pennsylvania, and new cryogenic and ultra-low service capabilities in Durham, North Carolina.
With a 55-year history as a trusted Contract Development and Manufacturing Organization (CDMO) partner for leading biopharma companies, Almac continues to enhance its global footprint and service offerings.
Specification:
Name: Almac Group New facilities
Type: New Construction
